I. COMMENCED TRADING IN AUGUST | ||||||||
Company |
Date |
Date |
Shares/ |
Price | Shares |
Lead, Other |
Gross |
Post- |
INITIAL OFFERINGS | ||||||||
Osiris |
5/12/06 |
8/4/06 |
3.5S |
$11 |
27.14 |
Jefferies and Co., Lazard Capital Markets, Leerink Swann & Co. |
$38.5 |
$298.5 |
OVERALLOTMENT OPTIONS | ||||||||
Replidyne Inc. |
4/6/06 |
8/2/06 |
0.5S |
$10 |
26.93 |
Merrill Lynch & Co.,Morgan Stanley & Co. (co-lead) Cowen & Co., Pacific Growth Equities |
$5 |
$269.3 |
Total: $43.5M | ||||||||
Number of IPOs in August: 1 | ||||||||
Average value of August IPOs: $38.5M | ||||||||
Number of IPOs in 2006: 19 | ||||||||
Total raised in IPOs in 2006: $867.98M | ||||||||
Average value of IPOs in 2006: $45.68M | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company |
Date |
Date |
Shares/ |
Price | Shares |
Lead, Other |
Gross |
Post- |
CV |
4/18/06 |
8/16/06 |
10.35S |
$9.50 |
56.66 |
Lehman Brothers, Merrill Lynch (co-lead) |
$98.33 |
$538.3 |
Total: $98.33 | ||||||||
Number of follow-on offerings in August: 1 | ||||||||
Average value of August follow-ons: $98.33 | ||||||||
Number of follow-on offerings in 2006: 26 | ||||||||
Total raised in follow-ons in 2006: $2,416.73M | ||||||||
Average value of follow-ons in 2006: $92.95M | ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization is calculated based on the offering price. | ||||||||
Currency conversions are based on exchange rates at the time of the deal. | ||||||||
1. Osiris raised $38.5M in an IPO. Underwriters have an option to purchase up to 525,000 additional shares to cover overallotments. | ||||||||
2. Underwriters of Replidyne's IPO that priced in June exercised their option to purchase about 500,000 additional shares. The IPO totaled about 5M shares and $50M in gross proceeds. | ||||||||
3. CV Therapeutics raised about $98.33M in a follow-on offering. Totals include the underwriters' purchase of 1.35M shares per their overallotment option. | ||||||||
II. FILED AND PENDING |
Company |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Value |
INITIAL OFFERINGS | ||||||
Achillion |
4/3/06 |
N/A |
N/A |
N/A |
Cowen & Co., CIBC World Markets (co-lead), JMP Securities |
$75 |
ActivBiotics |
8/14/06 |
N/A |
N/A |
N/A |
HSBC Securities, Needham & Co., BMO Capital Markets, Susquehanna Financial |
$46 |
Affymax Inc. |
7/28/06 |
N/A |
N/A |
N/A |
Morgan Stanley & Co., Cowen and Co. (co-lead), Thomas Weisel Partners (co-lead), RBC Capital Markets |
$115 |
BioVex |
6/20/06 |
N/A |
N/A |
N/A |
Janney Montgomery Scott, Stifel Nicolaus |
$45 |
Cadence |
7/17/06 |
N/A |
N/A |
N/A |
Merrill Lynch & Co., Deutsche Bank Securities (co-lead), Pacific Growth Equities, JMP Securities |
$86.25 |
Catalyst |
7/25/06 |
N/A |
N/A |
N/A |
First Albany Capital, Stifel Nicolaus (co-lead) |
$40.25 |
Emergent |
8/15/06 |
N/A |
N/A |
N/A |
JP Morgan Securities, Cowen and Co. (co-lead), HSBC Securities |
$86.25 |
ImaRx |
5/19/06 |
N/A |
N/A |
N/A |
CIBC World Markets, Jefferies & Co., First Albany Capital |
$75 |
Light Sciences |
4/21/06 |
N/A |
N/A |
N/A |
Cowen & Co., Wachovia Securities (co-lead), Jefferies & Co., Thomas Weisel Partners |
$86.25 |
Metabolix |
7/14/06 |
N/A |
N/A |
N/A |
Piper Jaffray & Co., Jefferies & Co., Thomas Weisel Partners, Ardour Capital Investments |
$86.25 |
Molecular |
11/8/05 |
N/A |
N/A |
N/A |
Piper Jaffray & Co., Cowen & Co. (co-lead), Oppenheimer & Co., Roth Capital Partners |
$57.5 |
Perlegen |
4/10/06 |
N/A |
N/A |
N/A |
Lehman Brothers, Deutsche Bank Securities (co-lead), Piper Jaffray & Co., Allen & Co. |
$115 |
Pharmasset |
5/9/06 |
N/A |
N/A |
N/A |
Banc of America Securities, UBS Investment Bank (co-lead), JMP Securities |
$75 |
PTC |
3/31/06 |
N/A |
N/A |
N/A |
Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities |
$86.25 |
Sucampo |
6/19/06 |
N/A |
N/A |
N/A |
Banc of America Securities, Deutsche Bank Securities (co-lead), Leerink Swann & Co. |
$86.25 |
Trubion |
6/2/06 |
N/A |
N/A |
N/A |
Morgan Stanley & Co., Banc of America Securities (co-lead), Pacific Growth Equities, Lazard Capital Market |
$86.25 |
FOLLOW-ON OFFERINGS | ||||||
Viragen Inc. |
7/31/06 |
77S and 77W |
$0.279 |
N/A |
Dawson James Securities |
$21.5 |
WITHDRAWN AND POSTPONED | ||||||
Company |
Date |
Shares/ Units |
Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value |
Amicus |
5/17/06/ |
N/A |
N/A |
N/A |
Morgan Stanley & Co., Goldman, Sachs & Co. (co-lead), Pacific Growth Equities |
$86.25 |
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
AMEX = American Stock Exchange. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
1. Achillion filed to raise up to $75M in an IPO. | ||||||
2. ActivBiotics filed to raise up to $46M in an IPO. | ||||||
3. Affymax filed to raise up to $115M in an IPO. | ||||||
4. BioVex filed to raise up to $45M in an IPO. | ||||||
5. Cadence filed to raise up to $86.25M in an IPO. | ||||||
6. Catalyst filed to raise up to $40.25M in an IPO. | ||||||
7. Emergent filed to raise up to $86.25M in an IPO. | ||||||
8. ImaRx filed to raise up to $75M in an IPO. | ||||||
9. Light Sciences Oncology filed to raise up to $86.25M in an IPO. | ||||||
10. Metabolix filed to raise up to $86.25M in an IPO. | ||||||
11. Molecular Insight filed to raise up to $57.5M in an IPO. | ||||||
12. Perlegen filed to raise up to $115M in an IPO. | ||||||
13. Pharmasset filed to raise up to $75M in an IPO. | ||||||
14. PTC Therapeutics filed to raise up to $86.25M in an IPO. | ||||||
15. Sucampo filed to raise up to $86.25M in an IPO. | ||||||
16. Trubion filed to raise up to $86.25M in an IPO. | ||||||
17. Viragen filed to raise up to $21.5M in a follow-on offering of stock and warrants. | ||||||
18. Amicus cited market conditions in withdrawing its proposed IPO. |